DNA Damage in AML-12 Hepatocytes and 3T3-L1 Adipocytes Treated with Clopidogrel
CURRENT DRUG SAFETY, vol.16, no.3, pp.252-258, 2021 (ESCI, Scopus)
- Publication Type: Article / Article
- Volume: 16 Issue: 3
- Publication Date: 2021
- Doi Number: 10.2174/1574886315666210106141936
- Journal Name: CURRENT DRUG SAFETY
- Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, PASCAL, Biotechnology Research Abstracts, EMBASE, MEDLINE
- Page Numbers: pp.252-258
- Keywords: AML-12 hepatocytes, 3T3-L1 adipocytes, clopidogrel, cell culture, DNA damage, DNA fragmentation, FATTY-ACID OXIDATION, IN-VIVO, INSULIN-RESISTANCE, CYTOCHROME-P450 3A, ADIPOSE-TISSUE, COMET ASSAY, ANTIPLATELET, TICLOPIDINE, CELLS, METABOLISM
- Istanbul University Affiliated: No
Abstract
Background: Clopidogrel has been commonly prescribed as a selective P2Y(12) receptor antagonist to reduce heart attack and stroke risk. Nearly 10% of absorbed clopidogrel is metabolized to active forms by cytochrome P450 (CYP) enzymes in the liver and 90% to inactive clopidogrel carboxylate by esterases.